IgA nephropathy testing method and test kit
There is provided a renal disease testing method comprising a complex detection step of detecting a complex of human uromodulin and human IgA in a sample derived from urine collected from a subject. It is preferred that the renal disease testing method of the invention further comprises a determination step of assessing the whether the renal disease is IgA nephropathy based on the ratio of the amount of the complex detected in the complex detection step to the amount of urinary proteins in the sample. The renal disease testing method of the invention has good detection sensitivity and specificity, and can conveniently and safely assess the existence of a renal disease (preferably, IgA nephropathy).
1. An immunoglobulin A (IgA) nephropathy testing method, comprising detecting a complex of human uromodulin and human IgA in a sample derived from urine collected from a human subject, wherein an elevated amount of the complex detected in the sample as compared to the amount of the complex present in urine of healthy persons is used to correlate the existence of IgA nephropathy in the human subject.
2. The method according to claim 1 , wherein detecting the complex comprises bringing the sample into contact with an antibody against human uromodulin and an antibody against human IgA.
3. The method according to claim 1 , further comprising obtaining a ratio of the amount of the complex detected to the amount of urinary proteins in the sample.
4. The method according to claim 3 , further comprising assessing the existence of IgA nephropathy on the basis of the ratio.
5. A renal disease testing method, comprising detecting a complex of human uromodulin and human IgA in a sample derived from urine collected from a human subject, wherein an elevated amount of the complex detected in the sample as compared to the amount of the complex present in urine of healthy persons is used to correlate the existence of a renal disease in the human subject, wherein the renal disease is IgA nephropathy, membranous nephropathy, systemic lupus erythematosus, focal glomerulosclerosis, minimal change nephrotic syndrome, or diabetic nephropathy.
6. The method according to claim 5 , wherein detecting the complex comprises bringing the sample into contact with an antibody against human uromodulin and an antibody against human IgA.
7. An IgA nephropathy testing method, comprising:
detecting a complex of human uromodulin and human IgA in a sample derived from urine collected from a human subject;
assessing the existence of a renal disease in the human subject on the basis of at least one of the amount of the complex detected or the amount of urinary proteins in the sample; and
assessing whether the renal disease is IgA nephropathy on the basis of a ratio of the amount of the complex detected to the amount of urinary proteins in the sample.
8. The method according to claim 1 , wherein detecting the complex comprises an immunochemical method using an antibody against human uromodulin and an antibody against human IgA.
9. The method according to claim 8 , wherein the immunochemical method is a sandwich method.
10. A method of detecting a complex of human uromodulin and human IgA, the method comprising bringing a sample derived from urine collected from a human subject into contact with an antibody against human uromodulin and an antibody against human IgA.
11. The method according to claim 10 , wherein the complex is detected by an immunochemical method using the antibody against the human uromodulin and the antibody against the human IgA.
12. The method according to claim 11 , wherein the immunochemical method is a sandwich method.
13. The method according to claim 10 , wherein the human subject is a person who has developed a renal disease, a person who is suspected to have developed a renal disease, or a person who has a possibility of developing a renal disease.
14. The method according to claim 13 , wherein the renal disease is IgA nephropathy.
15. A test kit for a renal disease selected from the group consisting of IgA nephropathy, membranous nephropathy, systemic lupus erythematosus, focal glomerulosclerosis, minimal change nephrotic syndrome, and diabetic nephropathy, comprising:
an antibody against human uromodulin and
an antibody against human IgA.
16. The test kit according to claim 15 , wherein the renal disease is IgA nephropathy.